Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
BACKGROUND
Ursodeoxycholic acid (UDCA) and its taurine conjugate (TUDCA) exert a protective effect in cholestatic liver diseases. A greater hepatoprotective effect of TUDCA has been suggested. Absorption appears to be a limiting factor and up to now has not been studied in man.


METHODS
We studied absorption and biliary bile acid secretion and composition after administration of UDCA and TUDCA in patients who had complete extrahepatic biliary obstruction caused by pancreatic carcinoma but had no intestinal or liver disease. After 5 days of intact enterohepatic circulation eight patients with a percutaneous biliary-duodenal drainage received, during two study periods, 1000 mg (1916.9 micromol; mean 29.6 micromol kg(-1)) TUDCA and 750 mg (1910.4 micromol; mean 29.5 micromol kg(-1)) UDCA in random order. Each patient served as his own control.


RESULTS
After UDCA and TUDCA administration the biliary UDCA content increased to 55.2% and 54.6% of total bile acids, respectively (not significant). Biliary secretion of cholic and chenodeoxycholic acids remained unchanged whereas that of lithocholic acid increased slightly. A total of 64.6% of the orally administered TUDCA and 55.1% of the UDCA was absorbed (not significant). After TUDCA administration, biliary UDCA was preferentially (95.4%) taurine-conjugated whereas after UDCA administration biliary UDCA was mainly (79.8%) glycine-conjugated.


CONCLUSIONS
After oral administration of TUDCA and UDCA, no significant differences in their absorption and in biliary bile acid secretion exist. Whether biliary enrichment with taurine conjugates of UDCA instead of glycine conjugates offers advantages in the treatment of cholestatic liver disease is unclear at present.
Rudolph
G
G
Department of Medicine, University of Heidelberg, Heidelberg, Germany.
Kloeters-Plachky
P
P
Sauer
P
P
Stiehl
A
A
D000368:Aged; D000704:Analysis of Variance; D001647:Bile Acids and Salts / Q000737:chemistry / Q000378:metabolism*; D001652:Bile Ducts / Q000378:metabolism*; D001651:Cholestasis, Extrahepatic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D008095:Lithocholic Acid / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000150:complications / Q000503:physiopathology; D013654:Taurine / Q000627:therapeutic use*; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D001647:Bile Acids and Salts; C030141:taurine-ursodeoxycholate conjugate; D013654:Taurine; D008095:Lithocholic Acid; D014580:Ursodeoxycholic Acid